Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Capricor TherapeuticsCAPR +0.34%37 Cash Ratio is 8.28 as of Mar. 2026, which is 82% above its 10-year median of 4.55. GuruFocus rates CAPR with a GF Score™ of 37/100 and a GF Value™ of $4.87 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 1,386 Biotechnology companies, Capricor Therapeutics ranks better than 75.69% on this metric.
Capricor Therapeutics has a Cash Ratio of 8.28. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Capricor Therapeutics's Cash Ratio or its related term are showing as below:
CAPR'
s Cash Ratio Range Over the Past 10 Years
Min: 0.74 Med: 4.55 Max: 18.9
Current: 8.28
During the past 13 years, Capricor Therapeutics's highest Cash Ratio was 18.90. The lowest was 0.74. And the median was 4.55.
CAPR's Cash Ratio is ranked better than 75.69% of 1386
companies
in the Biotechnology industry
Industry Median: 2.93
vs CAPR: 8.28
Capricor Therapeutics (NAS:CAPR) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Capricor Therapeutics's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Capricor Therapeutics Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Capricor Therapeutics's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Capricor Therapeutics's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Capricor Therapeutics (CAPR) has a Cash Ratio of 8.28 as of Mar. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Capricor Therapeutics and its competitors. This is 82% above median its historical median of 4.55. Over the past decade, Capricor Therapeutics' Cash Ratio has ranged from 0.74 to 18.90. According to the industry distribution chart, Capricor Therapeutics ranks #337 out of 1386 companies in the Biotechnology industry, placing it in the top 24.3%.
Is Capricor Therapeutics' Cash Ratio too high?
Capricor Therapeutics' current Cash Ratio of 8.28 is 82% above median its 10-year median of 4.55. Over the past 10 years, this metric has ranged from a low of 0.74 to a high of 18.90. The Biotechnology industry median Cash Ratio is 2.93. Capricor Therapeutics' value of 8.28 is 182.6% above this industry median. Based on the distribution chart, Capricor Therapeutics ranks #337 out of 1386 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Capricor Therapeutics has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Capricor Therapeutics' Cash Ratio compare to COAG and DMRA?
According to the Biotechnology industry distribution chart, Capricor Therapeutics ranks #337 out of 1386 companies for Cash Ratio. This places Capricor Therapeutics in the top 24% of its industry — outperforming the majority of peers. The industry median Cash Ratio is 2.93. Capricor Therapeutics' value of 8.28 is 182.6% above this benchmark. Historically, Capricor Therapeutics' own Cash Ratio has ranged from 0.74 to 18.90 over the past decade. While the company's 10-year median is 4.55 vs. the industry median of 2.93, Capricor Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.93, based on 1,386 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Capricor Therapeutics's current Cash Ratio of 8.28 is 182.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Capricor Therapeutics and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Capricor Therapeutics's current Cash Ratio is 8.28, which is 82% above median its own 10-year median of 4.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Capricor Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Capricor Therapeutics (CAPR) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.87, compared to a current price of $20.69 — trading 324.8% above its estimated fair value. The current Cash Ratio is 8.28, which is 82% above median its 10-year median of 4.55 and 182.6% above the Biotechnology industry median of 2.93. Capricor Therapeutics' overall GF Score™ is 37/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Capricor Therapeutics (CAPR), the current Cash Ratio is 8.28 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Capricor Therapeutics (CAPR) Overvalued in 2026?
Based on GuruFocus' analysis, Capricor Therapeutics stock appears to be overvalued.
The current stock price of $20.69 is trading 324.8% above its estimated GF Value™ of $4.87.
GuruFocus considers Capricor Therapeutics to be Significantly Overvalued.
Key valuation signals for CAPR:
Cash Ratio: 8.28 (82% above median its 10-year median of 4.55)
GF Value™: $4.87 vs. price of $20.69 (324.8% above fair value)
Industry Position: 182.6% above the Biotechnology median (#337 of 1386)
No single metric tells the full story. See the CAPR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
37GF Score
Get the complete analysis for CAPR
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAPR has been successfully added to your 
